

Corporate Accountability for Tax Expenditures Act 93-552

Annual Project Progress Reports for 2023

Xeris Pharmaceuticals, Inc.

Chicago

I. Development Assistance Agreements Awarded in 2017

	Assistance Amount	Agreement Number
EDGE Tax Credit	1,012,296.31	17 ZCA1088

II. Organization/Project Site Information

Chief Officer or authorized designee	Blaine Roeder
Title	Tax Director
Address	180 N LaSalle
	Suite 1600
	Chicago, IL 60601
	USA
Phone	312-517-1997
E-mail	broeder@xerispharma.com
Standard Industrial Classification Number (SIC#)	2834
North American Industry Classification System (NAICS)	325412

III. Did the recipient's use of the State Funding reduce employment at any other site in Illinois? No

Corporate Accountability for Tax Expenditures Act 93-552

Annual Project Progress Reports for 2023

Xeris Pharmaceuticals, Inc.

Chicago

IV. Job Creation and Retention Data

Program Type EDGE Tax Credit

Agreement Number 17 ZCA1088

Assistance Amount 1,012,296.31

Report Header Definitions	
Wages	Average Annual Salary by Classifications
Full-Time	Permanent Full-Time
+/-	Gain or (Loss)

Number of Employees At the Time of Application

Job Classification	Avg Annual Salary	Positions	Full-Time	Part-Time	Temporary
Headquarters	865000.00	3	3	0	0
Finance	185000.00	1	1	0	0
Marketing	175000.00	1	1	0	0
Operations	0.00	0	0	0	0
Clinical	0.00	0	0	0	0
IT	0.00	0	0	0	0
Legal	0.00	0	0	0	0
Quality Assurance	0.00	0	0	0	0
Regulatory	0.00	0	0	0	0
Medical Affairs	0.00	0	0	0	0
Sales	0.00	0	0	0	0
Supply Chain	0.00	0	0	0	0
Product Development	0.00	0	0	0	0
Totals:		5	5	0	0

Corporate Accountability for Tax Expenditures Act 93-552

Annual Project Progress Reports for 2023

Xeris Pharmaceuticals, Inc.

Chicago

Number of Employees As of the Date of the Report (12/31/2023)

Job Classification	Avg Annual Salary	Positions	Full-Time	+/-	Part-Time	+/-	Temporary	+/-
Headquarters	163089.00	10	10	7	0	0	0	0
Finance	192595.00	13	13	12	0	0	0	0
Marketing	165737.00	13	13	12	0	0	0	0
Operations	170997.00	3	3	3	0	0	0	0
Clinical	142219.00	3	3	3	0	0	0	0
IT	180910.00	7	7	7	0	0	0	0
Legal	361037.00	3	3	3	0	0	0	0
Quality Assurance	141700.00	7	7	7	0	0	0	0
Regulatory	244493.00	2	2	2	0	0	0	0
Medical Affairs	237512.00	14	14	14	0	0	0	0
Sales	81703.00	60	60	60	0	0	0	0
Supply Chain	141894.00	6	6	6	0	0	0	0
Product Development	93891.00	18	18	18	0	0	0	0
Totals:		159	159	154	0	0	0	0

Number of Jobs Stated in the Agreement that would be Created at the Site as a Result of Assistance

Job Classification	Avg Annual Salary	Positions	Full-Time	Part-Time	Temporary
Director of Business Development	175000.00	1	1	0	0
Finance	965000.00	8	8	0	0
Headquarters	235000.00	1	1	0	0
Marketing	250000.00	2	2	0	0
Operations	570000.00	3	3	0	0
Regulatory	235000.00	1	1	0	0
Totals:		16	16	0	0

Number of Jobs Stated in the Agreement that would be Retained at the Site as a Result of Assistance

Job Classification	Avg Annual Salary	Positions	Full-Time	Part-Time	Temporary
NONE	0.00	0	0	0	0
Totals:		0	0	0	0

Corporate Accountability for Tax Expenditures Act 93-552

Annual Project Progress Reports for 2023

Xeris Pharmaceuticals, Inc.

Chicago

Number of Full-Time Permanent Employees Anticipated To Be Hired at this Site on 12/31/2023

Job Classification	Anticipated Starting Dates	Number of Positions to be Hired in this Category	Average Annual Wage per New Employee	Total New Payroll to be Created
NONE		0	\$0.00	\$0.00
Totals:		0		\$0.00

Job Creation Data Explanatory Notes

If the change (gain/loss) in the number of full-time permanent employees as of the date of the report plus the number of full-time permanent employees anticipated to be hired after date of the report does not equal the number of full-time permanent employees stated in the Agreement that would be created at the site as a result of the assistance, then please explain why not:

Due to the expanding business, more employees were hired in the Chicago location than originally expected. Also, the Company expanded the Chicago Corporate Headquarters to facilitate the increase in headcount.

Corporate Accountability for Tax Expenditures Act 93-552

Annual Project Progress Reports for 2023

Xeris Pharmaceuticals, Inc.

Chicago

I, Steve Pieper, as the chief officer or authorized designee of the recipient, verify that the information in the progress report contains no knowing misrepresentation of material facts upon which eligibility for development assistance is based. I further certify that, to the best of my knowledge, the recipient is in compliance with the development assistance agreement(s) between, or on behalf of, the recipient and the Illinois Department of Commerce and Economic Opportunity and/or the Illinois Department of Transportation and/or the office of the Illinois State Treasurer

Signature on File

4/8/2024

Signature

Date

Chief Financial Officer

Title